2017 Press Releases

2017 Press Releases
Home / 2017 Press Releases

2017 Press Releases


Protalix BioTherapeutics Provides Review of 2016 and Strategic Outlook for 2017

Full Switch Plan Initiated and Published by Brazilian Ministry of Health for Gaucher Patients in Brazil Yielding Significant Revenue Stream Fabry Phase III Clinical Trial Underway with Interim Results Expected in 2018 Phase II Clinical Trial for Cystic Fibrosis Positive Interim Data Reported with Full Results Expected During First Quarter of 2017 Phase II Clinical Trial of Oral anti TNF for Ulcerative Colitis Initiated with Results Expected in Second Half of 2017 New Pipeline Candidate... 

Protalix BioTherapeutics Announces Positive Interim Results from Phase II Clinical Trial of alidornase alfa (AIR DNase™) for the Treatment of Cystic Fibrosis

CARMIEL, Israel, Jan. 03, 2017 (GLOBE NEWSWIRE) -- Protalix BioTherapeutics, Inc. (NYSE MKT:PLX) (TASE:PLX), announced today positive interim results from the Company’s phase II clinical trial of alidornase alfa for the treatment of Cystic Fibrosis (CF) for the first 13 CF patients enrolled in the study.  Fifteen patients have been enrolled in, and are expected to complete, the study.  alidornase alfa is a plant cell expressed, chemically modified recombinant DNase enzyme resistant to inhibiti...